Clinical Trial

QT Interval Effects Study of Oral FXS5626 Tablets

Name: QT Interval Effects Study of Oral FXS5626 Tablets — clinical trial record (NCT07695779)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc interval of a single oral dose of FXS5626 in healthy subjects.

Trial Details

NCT Number	NCT07695779
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions	Evaluation of QTc Interval
Enrollment	28 participants
Start Date	2026-08-05
Primary Completion	2026-09-25 (estimated)
Study Completion	2026-09-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-10